

1 **Article**

2 **Immune evolution from preneoplasia to invasive lung adenocarcinomas and**  
3 **underlying molecular features**

4 **Authors:** Hitoshi Dejima<sup>1,17</sup>, Xin Hu<sup>2,17</sup>, Runzhe Chen<sup>3,17</sup>, Jiexin Zhang<sup>4,17</sup>, Junya  
5 Fujimoto<sup>1,17</sup>, Edwin R. Parra<sup>1</sup>, Cara Haymaker<sup>1</sup>, Shawna Hubert<sup>3</sup>, Dzifa Duose<sup>1</sup>, Luisa M.  
6 Solis<sup>1</sup>, Dan Su<sup>5,6</sup>, Junya Fukuoka<sup>7</sup>, Kazuhiro Tabata<sup>7</sup>, Hoa Pharm<sup>7</sup>, Nicholas  
7 Mcgranahan<sup>8</sup>, Baili Zhang<sup>1</sup>, Jie Ye<sup>3</sup>, Lisha Ying<sup>5,9</sup>, Latasha Little<sup>2</sup>, Curtis Gumbs<sup>2</sup>, Chi-  
8 Wan Chow<sup>1</sup>, Marcos Roberto Estecio<sup>10,11</sup>, Myrna C.B. Godoy<sup>12</sup>, Mara B. Antonoff<sup>13</sup>, Boris  
9 Sepesi<sup>13</sup>, Harvey Pass<sup>14</sup>, Carmen Behrens<sup>3</sup>, Jianhua Zhang<sup>2</sup>, Ara A. Vaporciyan<sup>13</sup>, John  
10 V. Heymach<sup>3</sup>, Paul Scheet<sup>15</sup>, J. Jack Lee<sup>16</sup>, P. Andrew Futreal<sup>2</sup>, Alexandre Reuben<sup>3\*</sup>,  
11 Humam Kadara<sup>1\*</sup>, Ignacio Wistuba<sup>1\*</sup>, Jianjun Zhang<sup>2, 3,18\*</sup>

12

13 **Affiliations**

14 Departments of <sup>1</sup>Translational Molecular Pathology, <sup>2</sup>Genomic Medicine, <sup>3</sup>Thoracic/Head  
15 and Neck Medical Oncology, <sup>4</sup>Bioinformatics & Computational Biology, <sup>10</sup>Epigenetics and  
16 Molecular Carcinogenesis, <sup>11</sup>Center of Cancer Epigenetics, <sup>12</sup>Thoracic Imaging,  
17 <sup>13</sup>Thoracic and Cardiovascular Surgery, <sup>15</sup>Epidemiology, <sup>16</sup>Biostatistics, The University of  
18 Texas MD Anderson Cancer Center, Houston, Texas, USA.

19 <sup>5</sup>Institute of Cancer and Basic Medicine (IBMC), Chinese Academy of Sciences,  
20 Hangzhou, China.

21 <sup>6</sup>Department of Pathology, <sup>9</sup>Zhejiang Cancer Research Institute, Cancer Hospital of the  
22 University of Chinese Academy of Sciences (Zhejiang Cancer Hospital), Hangzhou,  
23 China.

24 <sup>7</sup>Department of Pathology, Nagasaki University Graduate School of Biomedical Sciences,  
25 Nagasaki, Japan.

26 <sup>8</sup>Cancer Research United Kingdom-University College London Lung Cancer Centre of  
27 Excellence, London, UK.

28 <sup>14</sup>Department of Cardiothoracic Surgery, New York University Langone Medical Center,  
29 New York, NY 10016, USA.

30 <sup>17</sup>These authors contributed equally

31 <sup>18</sup>Lead Contact

32 \*Correspondence: [AReuben@mdanderson.org](mailto:AReuben@mdanderson.org) (A.R), [HKadara@mdanderson.org](mailto:HKadara@mdanderson.org)  
33 (H.K.), [liwistuba@mdanderson.org](mailto:liwistuba@mdanderson.org) (I.W.), [Jzhang20@mdanderson.org](mailto:Jzhang20@mdanderson.org) (J.Z.)

34

## 35 **SUMMARY**

36 How anti-cancer immunity shapes early carcinogenesis of lung adenocarcinoma (ADC)  
37 is unknown. We characterized immune contexture of invasive lung ADC and its  
38 precursors by transcriptomic immune profiling, T cell receptor (TCR) sequencing and  
39 multiplex immunofluorescence. Our results demonstrated that anti-tumor immunity  
40 evolved as a continuum from lung preneoplasia, to preinvasive ADC, minimally-invasive  
41 ADC and frankly invasive lung ADC with a gradually less effective and more intensely  
42 regulated immune response including down-regulation of immune-activation pathways,

43 up-regulation of immunosuppressive pathways, higher infiltration of CD4+ T cells, lower  
44 infiltration of CD8+ T cells, decreased T cell clonality, and lower frequencies of top T cell  
45 clones in later stages. Driver mutations, HLA loss, chromosomal copy number aberrations  
46 and DNA methylation changes may collectively impinge host immune responses and  
47 facilitate immune evasion as a potential mechanism underlying outgrowth of the most fit  
48 subclones in preneoplasia into dominant clones in invasive ADC.

49

## 50 **SIGNIFICANCE**

51 There has been a drastic increase in the detection of lung nodules, many of which are  
52 lung ADC precursors. The management of these lung nodules is controversial. We  
53 discovered that immune activation and evasion have started at preneoplastic stage and  
54 lung ADC precursors may exhibit an overall better-preserved anti-tumor immune  
55 contexture suggesting therapeutic strategies reprogramming the immune  
56 microenvironment in patients with lung ADC precursors prior to further  
57 immunosuppression in invasive lung cancers may be beneficial. These findings have  
58 served as the critical scientific rationale for our immunoprevention clinical trial IMPRINT-  
59 Lung (NCT03634241) recruiting individuals diagnosed with lung nodules at high risk  
60 developing invasive lung cancers.

## 61 **KEYWORDS**

62 Lung adenocarcinoma, premalignancy, atypical adenomatous hyperplasia,  
63 adenocarcinoma *in situ*, minimally invasive adenocarcinoma, tumor evolution, early  
64 carcinogenesis, immunoediting, immune microenvironment, immunogenomics

## 65 INTRODUCTION

66 Despite significant advances in its management, lung cancer remains the leading cause  
67 of cancer death worldwide (Siegel et al., 2020; Tan et al., 2016), largely due to late  
68 diagnosis at advanced stages when cures are generally unachievable (Barnett, 2017;  
69 Borghaei et al., 2015; Siegel et al., 2020). Computed tomography (CT) scan-guided lung  
70 cancer screening has demonstrated a reduction of lung cancer mortality by 26%-61% (de  
71 Koning et al., 2020) highlighting the importance of early detection and intervention. These  
72 findings suggest that early cancer interception is crucial to reduce lung cancer incidence  
73 and mortality. Yet, to date, randomized clinical trials on primary lung cancer prevention  
74 have only produced disappointing results (de Koning et al., 2020), primarily due to our  
75 rudimentary knowledge of early phases in lung cancer development. Improved  
76 understanding of targetable molecular mechanisms underlying early lung carcinogenesis  
77 may accelerate the development of precise diagnostic as well as effective preventive and  
78 therapeutic strategies.

79 Lung adenocarcinoma (ADC) is the most common histological subtype of lung cancer.  
80 Recent studies has postulated that lung ADC may arise from atypical adenomatous  
81 hyperplasia (AAH), the only recognized preneoplasia to lung ADC (Aoyagi et al., 2001;  
82 Chiosea et al., 2007; Kitamura et al., 1999; Maeshima et al., 2010; Min et al., 2010;  
83 Noguchi, 2010; Seki and Akasaka, 2007), which evolves into preinvasive  
84 adenocarcinoma *in situ* (AIS) (Weichert and Warth, 2014), to micro-invasive lesion termed  
85 minimally invasive adenocarcinoma (MIA) (Aoyagi et al., 2001; Travis et al., 2011) and  
86 eventually frankly invasive ADC (Aoyagi et al., 2001; Travis et al., 2011). Early-stage lung  
87 ADCs and their precursors usually present as lung nodules with distinct radiologic

88 features called ground glass opacity (GGO). These lung nodules are often referred as  
89 indeterminate pulmonary nodules (IPN) without histologic diagnosis as the diagnostic  
90 yield from biopsy of GGO-predominate nodules is low and surgery is not the standard of  
91 care. This has subsequently led to the scarcity of appropriate materials to study the  
92 molecular profiles of lung ADC precursors (Izumchenko et al., 2015).

93 Carcinogenesis results from progressive accumulation of molecular abnormalities  
94 (molecular evolution) (Vogelstein et al., 2013) and escape from host immune surveillance  
95 (immunoediting) (Schreiber et al., 2011). Our recent gene expression and genomic pilot  
96 studies on lung ADC precursors have demonstrated distinct transcriptomic features  
97 (Sivakumar et al., 2017) and progressive genomic evolution along the spectrum of AAH  
98 to AIS, MIA and ADC (Hu et al., 2019). However, the extent to which immunoediting  
99 sculpts early carcinogenesis of lung ADC and the underlying genomic and epigenetic  
100 alterations associated with these immune features still remain to be determined. In the  
101 current study, we performed immune gene expression profiling, T cell receptor (TCR)  
102 sequencing and multiplex immunofluorescence (mIF) staining on a cohort of resected  
103 AAH, AIS, MIA and invasive ADC lesions and paired morphologically normal lung tissues  
104 (NL) to delineate the evolution of immune contexture, particularly T cell landscape across  
105 different stages of early lung ADC pathogenesis. We further leveraged whole exome  
106 sequencing (WES) (Hu et al., 2019) and methylation data (Hu et al., 2020) from the same  
107 cohort of IPNs to underscore the genomic and epigenetic alterations that may impinge on  
108 these immune features (**Table S1** and **Figure 1**).

109

## 110 **RESULTS**

111 **Progressive decrease in overall immunity mirrors evolution from preneoplasia to**  
112 **invasive lung adenocarcinoma**

113 To assess dynamic changes in the immune contexture during early lung carcinogenesis,  
114 we performed immune profiling using the nCounter PanCancer Immune Profiling Panel  
115 (NanoString), which includes 770 genes from 14 different immune cell types, common  
116 checkpoint inhibitors, cancer/testis antigens, and genes covering both the adaptive and  
117 innate immune response (Chen et al., 2016) on 47 resected pulmonary nodules (n=9 for  
118 AAH, n=11 for AIS, n=21 for MIA, and n=6 for invasive ADC) and paired NL tissues (n=38).  
119 There were no differences in age (p=0.55, Kruskal-Wallis test), sex (p=0.31, fisher's exact  
120 test) or smoking status (p=0.35, fisher's exact test) between patients with pulmonary  
121 nodules of different histologic stages. In total, 291 genes were differentially-expressed  
122 (DEGs). Interestingly, changes in the majority of DEGs, regardless of their direction,  
123 exhibited a progressive pattern along the spectrum from NL, to AAH, AIS, MIA and ADC  
124 (**Table S2**). Examples of progressively increased genes included immune suppressive  
125 genes *CD47* (protection of cancer cells from immune cell killing) (Soto-Pantoja et al.,  
126 2014), *CD276* (inhibition of immune responses) (Picarda et al., 2016) and *CTLA4*  
127 (checkpoint molecule) (Pardoll, 2012), while progressively decreased genes included  
128 *ENTPD1* (expressed on tumor-specific T cells) (Bastid et al., 2013), granzyme B (*GZMB*)  
129 and perforin 1 (*PRF1*) (two cytotoxic molecules produced by T lymphocytes and natural  
130 killer cells (NK cells) (Prakash et al., 2014; Tschopp et al., 1986) (**Figure S1**). Functional  
131 pathway analysis of DEGs revealed 26 significantly de-regulated pathways associated  
132 with neoplastic evolution from NL to invasive ADC, of which, 23 were down-regulated  
133 (**Figure 2A**). On the other hand, all three up-regulated pathways (systemic lupus

134 erythematosus (SLE) in B cell signaling, T cell exhaustion signaling and PARP signaling  
135 pathways) could potentially impair immune response (Pan et al., 2020; Pantelidou et al.,  
136 2019; Wherry and Kurachi, 2015). These results indicated an overall decreased immunity  
137 in later-stage lesions.

138 We next de-convoluted gene expression profiling data using TIMER (Li et al., 2020) to  
139 evaluate changes in immune cell composition. As shown in **Figure 2B**, CD4+ T  
140 lymphocyte infiltration progressively increased from NL to invasive ADC. Conversely,  
141 infiltration of CD8+ T lymphocytes progressively decreased with neoplastic evolution  
142 (**Figure 2C**) leading to significantly higher CD4/CD8 ratio in later-stage lesions (**Figure**  
143 **2D**). Additionally, B cell infiltration progressively increased along the spectrum from NL  
144 to invasive ADC (**Figure 2E**). Of particular interest, all 6 tertiary lymphoid structure (TLS)  
145 markers CD19, MS4A1 (CD20), CXCL13, CXCR5, CCR7 and CCL19 (Cabrita et al., 2020)  
146 (**Figure S2**) also progressively increased from NL to invasive ADC indicating a  
147 progressive TLS aggregation, which may play a role in follicular regulatory T cell-  
148 mediated CD8+ T cell exclusion (Wang et al., 2020). Indeed, these TLS markers were  
149 positively associated with CD4+ T cell infiltration, but negatively associated with CD8+ T  
150 cell infiltration (**Figure S3**). To validate these findings, we applied TIMER to RNAseq data  
151 from an independent cohort previously published by our group and observed similar  
152 results (**Figure S4**) (Sivakumar et al., 2017).

153 Taken together, these results suggest that immune evolution progressed as a continuum  
154 from preneoplasia to invasive lung ADC with a gradually less effective and more intensely  
155 regulated immune response.

156

157 **Dynamic changes in T cell phenotype and infiltration define histologic stages of**  
158 **early ADC development**

159 We next performed multiplex immunofluorescence (mIF) using antibodies against  
160 cytokeratin (CK), CD3, CD8, PD-1, PD-L1, CD68, CD45RO, GZMB and FoxP3 (**Figure**  
161 **3A, Figure S5** and **Figure S6**) on a subset of pulmonary nodules (n=9 for AAH, n=10 for  
162 AIS, n=21 for MIA, and n=6 for invasive ADC) and paired NL (n =7) to assess the dynamic  
163 changes of various subtypes of T cells and their interaction with (pre-)malignant cells  
164 during early lung carcinogenesis. Densities of infiltrating activated CTLs  
165 (CD3+CD8+GZMB+) and regulatory T cells (Treg, CD3+CD8-FoxP3+) assessed by mIF  
166 were positively correlated with corresponding CD8+ and CD4+ T cell infiltrate levels  
167 derived from gene expression profiling, respectively (**Figure S7A-B**). Furthermore,  
168 Treg/activated CTL ratio closely recapitulated CD4/CD8 ratio inferred from immune gene  
169 expression profiling (**Figure S7C**). Correlations among immune subsets and between  
170 immune components and epithelial cells across IPNs of different histologic stages  
171 demonstrated that in normal tissues, densities of CK+ and CK+PD-L1+ cells were  
172 positively correlated, as were Tregs and memory T cells, cytotoxic and activated cytotoxic  
173 T cells (**Figure S8A**). For AAH, only total macrophages and activated cytotoxic T cells  
174 were positively correlated (**Figure 3B**). In AIS, PD-L1+ macrophages were positively  
175 correlated with Tregs, antigen-experienced T cells and cytotoxic T cells (**Figure 3C**). For  
176 MIA, CK cells were negatively correlated with total macrophages and memory T cells,  
177 while Tregs were positively correlated with antigen-experienced T cells and memory T  
178 cells were correlated with cytotoxic and activated cytotoxic T cells (**Figure 3D**). Finally, in  
179 ADC, PD-L1+CK+ cells were correlated with total and PD-L1+ macrophages, PD-L1+



180 macrophages were correlated with total macrophages, and Tregs were correlated with  
181 memory T cells (**Figure S8B**). Overall, relationships between cell types varied widely  
182 across stages, highlighting the dynamic nature of tumor-immune interactions during tumor  
183 evolution.

184

### 185 **Progressively divergent TCR repertoire with neoplastic progression**

186 Because of the central role of T cells in tumor surveillance, we next sought to investigate  
187 the T cell repertoire (Shah et al., 2011) by multiregional T cell receptor (TCR) sequencing  
188 on 13 AAH, 11 AIS, 23 MIA and 10 ADC as well as 49 NL. We first assessed the T cell  
189 diversity using Inverse Simpson Index (Kaplinsky and Arnaout, 2016). T cell diversity was  
190 positively correlated with infiltration of CD4+ T cells derived from gene expression profiling  
191 (**Figure S9A**) as well as densities of Tregs from mIF (**Figure S9B**) and increased steadily  
192 from AAH to AIS, MIA and ADC ( $p < 0.0001$ ) (**Figure 4A**) in line with higher CD4+ T cells  
193 in later stage lesions (**Figure 2B**). We then compared the distributions of T cell clonality  
194 across histologic stages, focusing on the most expanded T cell clones (Mansfield et al.,  
195 2018; Wang et al., 2019). As shown in **Figure 4B** and **Figure S10**, the top 10, 100, 200,  
196 and 500 clones accounted for a higher frequency in the NLs, and gradually decreased in  
197 AAH, AIS, MIA and invasive ADC ( $p < 0.0001$ ) implying suppressed T cell expansion  
198 during early carcinogenesis of lung ADC.

199

### 200 **Suppression of the T cell repertoire may occur at the preneoplastic stage**

201 To further understand the T cell response at different histologic stages, we calculated T  
202 cell clonality, a metric indicating expansion and activation of T cell clones. T cell clonality  
203 was positively correlated with infiltration of CD8+ T cells ( $r=0.561$ ,  $p=4.863e-06$ ),  
204 activated CTLs ( $r=0.318$ ,  $p=7.340e-03$ ), *GZMB* expression ( $r=0.319$ ,  $p=5.068e-02$ ) and  
205 Th1 cytokines ( $r=0.473$ ,  $p=3.923e-05$ ) (**Figure S11A-D**), while negatively correlated with  
206 infiltration of CD4+ T cells ( $r=-0.385$ ,  $p=8.993e-04$ ) and Tregs ( $r=-0.477$ ,  $p=2.965e-05$ )  
207 (**Figure S11E-F**) suggesting that T cell clonality was mainly driven by clonal expansion  
208 of activated CTLs, with Tregs inhibiting CTL responses. Comparing T cell clonality among  
209 different stages revealed the highest clonality in NL (**Figure 4C**) consistent with our  
210 previous findings (Reuben et al., 2020). T cell clonality declined from NL to AAH  
211 increasing in AIS/MIA and declining to its lowest level in ADC (**Figure 4C**). These results  
212 suggest that early ADC pathogenesis is associated with local immunosuppression in TCR  
213 repertoire that may have commenced at the preneoplastic stage.

214

### 215 **Driver mutations affect the immune response in pre/early ADC**

216 We next sought to explore the molecular features associated with the immune contexture  
217 observed in these lesions. We first explored the two most frequently mutated driver genes  
218 in this cohort *EGFR* and *KRAS* (Hu et al., 2019). Compared to *EGFR*-mutant lesions or  
219 double wild-type lesions, *KRAS*-mutant lesions exhibited highest CD8+ T cell infiltration  
220 and lowest CD4/CD8 T cell ratio inferred from immune gene expression; highest CTL  
221 infiltration, highest effector memory cytotoxic T cell infiltration, highest CTL/Treg ratio from  
222 mIF as well as highest T cell clonality measured by TCR sequencing (**Figure S12**). These  
223 trends remained similar when analyzing each histologic stage (**Figure S13**). These

224 findings are consistent with our previous studies in invasive lung cancers (Reuben et al.,  
225 2020) and emphasize the interplay between oncogene mutations and immune  
226 surveillance during early pathogenesis of lung adenocarcinoma.

227

## 228 **Chromosomal copy number variations and HLA loss may contribute to impaired T** 229 **cell responses**

230 In light of recent studies suggesting immune evasion could be facilitated by an inability to  
231 present neoantigens due to loss of HLA (McGranahan et al., 2017), we applied the  
232 LOHHLA (loss of heterozygosity in HLA) algorithm (McGranahan et al., 2017) to WES  
233 data from these lesions (Hu et al., 2019). LOH at the HLA loci was observed in 7%, 15%  
234 and 33% of AIS, MIA and ADC respectively, but in none of AAH lesions (**Figure S14A**,  
235  $p=0.005$ , Chi-Square test). Correlation with T cell infiltration derived from immune gene  
236 expression profiling demonstrated that lesions with HLA LOH had similar CD4+ T cell  
237 infiltration, but trends of lower CD8+ T cell infiltration and higher CD4/CD8 ratio although  
238 the difference did not reach statistical significance (**Figure S14B-D**).

239 Chromosomal copy number variation (CNV) has been reported to impact immune  
240 microenvironment across different cancers (Davoli et al., 2017). We next investigated  
241 whether CNV affected the immune landscape of these lung ADC precursors. Correlation  
242 with T cell infiltration derived from gene expression profiling demonstrated burden of  
243 allelic imbalance (AI), a subtle form of CNV, was negatively correlated with CD8+ T cell  
244 infiltration, but positively correlated with CD4+ T cell infiltration and CD4/CD8 T cell ratio  
245 (**Figure S15A-C**). Similar trend was also observed with CNV burden, although these

246 differences did not reach statistical significance (**Figure S15D-F**). Interestingly, HLA-LOH  
247 positive lesions exhibited significantly higher AI burden and CNV burden compared to  
248 that of HLA-LOH negative lesions (**Figure S16**). One plausible explanation is that the  
249 development AI, CNV or HLA LOH resulted from chromosomal instability (CIN) and cell  
250 clones with CIN may lead to higher CNV/AI burdens as well as increased likelihood of  
251 HLA loss, which could subsequently enable these cells escaping from anti-tumor immune  
252 surveillance and developing into dominant clones in the later-stage of neoplastic lesions.

253

#### 254 **Methylation status interacts with genomic alterations and impacts the immune** 255 **response during early lung cancer pathogenesis**

256 Somatic mutations play central roles in activating anti-tumor immune responses through  
257 generating neoantigens that can be recognized by T cells (McGranahan et al., 2016;  
258 Yarchoan et al., 2017). As shown in **Figure S17**, a progressive increase in total mutation  
259 burden was observed from AAH to AIS, MIA and ADC. However, analysis of methylation  
260 data from reduced representation bisulfite sequencing (RRBS) of the same cohort of IPNs  
261 (Hu et al., 2020) revealed that a significantly larger proportion of genes exhibited promoter  
262 hypermethylation (>30% CpG methylated) in later-stage lesions, thus potentially  
263 dampening the expression of neoantigens in later stage lesions. These data suggest that  
264 promoter hypermethylation could contribute to neoantigen depletion and immune escape.  
265 Furthermore, we assessed the impact of global methylation status, using long  
266 interspersed transposable elements-1 (LINE-1) as a surrogate marker (Kankava et al.,  
267 2018; Ohka et al., 2011; Saito et al., 2010), on the immune microenvironment in these  
268 lesions. Overall, global methylation level was negatively associated with CD4+ T cell

269 infiltration and CD4/CD8 ratio derived from gene expression profiling, Tregs infiltration  
270 and Treg/CD8 ratio from mIF (**Figure S18**) suggesting decreased global methylation was  
271 associated suppressive immune contexture.

272

## 273 **DISCUSSION**

274 Cancer evolution is shaped by the interaction between cancer cells and host immune  
275 surveillance, a process termed immunoediting consisting of elimination, equilibrium, and  
276 escape phases (Dunn et al., 2002; Dunn et al., 2004a; Dunn et al., 2004b). It is well  
277 documented that the majority of human cancers are infiltrated with various immune cells,  
278 but often in an immunosuppressive microenvironment as remnant evidence of  
279 immunoediting (Mittal et al., 2014; O'Donnell et al., 2019). T cell immunity is significantly  
280 compromised even in stage I lung cancers (Lavin et al.; Reuben et al., 2020) indicating  
281 that these cancers have already begun evading immune surveillance. However, when  
282 and how the elimination and equilibrium phases occur over the lung cancer evolution  
283 continuum is unknown. Therefore, investigating the molecular and immune landscape of  
284 lung premalignancies is warranted to elucidate the timing of immune activation/evasion  
285 and its underlying molecular mechanisms during early lung carcinogenesis.

286 In the current study, we leveraged a relatively large cohort of resected lung ADC  
287 precursors with available genomic and epigenetic profiling data to characterize the  
288 dynamic changes in the immune contexture across different consecutive developmental  
289 stages by gene expression profiling, mIF and TCR sequencing. To the best of our  
290 knowledge, this is the first systemic and comprehensive study on immune evolution

291 during early carcinogenesis of lung ADC and its potential underlying molecular basis.  
292 Overall, there was a more suppressive and tightly controlled immune response,  
293 particularly T cell response, in later stage lesions highlighting that the dynamic  
294 interaction between cancer cells and host immune surveillance was overall evolving  
295 toward immune escape along with pathogenesis of lung ADC. Notably, dynamic  
296 changes in immune contexture progressed as a continuum from preneoplasia AAH to  
297 pre-invasive AIS, to micro-invasive MIA and finally frankly invasive ADC without obvious  
298 “step-wise” major leaps at transitions between different histologic stages. This is  
299 consistent with the overall progressive genomic evolution from AAH to AIS, MIA and ADC  
300 (Hu et al., 2019) suggesting that early carcinogenesis of lung ADC is a gradual process  
301 shaped by continuous interaction with host immune surveillance. Importantly, dynamic  
302 immune activation and suppression have already started at preneoplastic stage. This  
303 is in line with a similar study on lung squamous cell carcinoma (SCC) precursors by  
304 Mascaux and colleagues, which revealed evidence of both immune activation and  
305 evasion along with evolution of preinvasive SCC lesions (Mascaux et al., 2019). Taken  
306 together, these data advocate for therapy targeting the immune microenvironment in  
307 patients with lung cancer precursors to prevent development of invasive lung cancers.

308 Identification of the molecular basis underlying immune activation and evasion may  
309 provide novel insights for understanding tumor-immune interactions and establishing  
310 biomarkers to select patients who may benefit from immunoprevention. WES and RRBS  
311 data available from the same cohort of pulmonary nodules provided the opportunity to  
312 depict the genomic and epigenetic features associated with the distinct immune  
313 landscape (Hu et al., 2020; Hu et al., 2019). Overall, oncogene mutations, HLA loss, CNV

314 burden, AI burden and methylation status were all found to associate with the immune  
315 contexture, similarly to advanced cancers (Fridman et al., 2017; Thorsson et al., 2018).  
316 For example, *KRAS* mutations correlated with more active immune response, while  
317 *EGFR* mutations, HLA loss, higher CNV burden and decreased global methylation status  
318 correlated with a cold immune microenvironment. However, associations with any single  
319 genomic or epigenetic feature were weak, suggesting heterogenous but convergent  
320 evolution towards immune escape during early lung carcinogenesis.

321 Our previous work suggested that early lung ADC carcinogenesis may predominantly  
322 follow the clonal sweep model, whereby certain subclones in early-stage preneoplasia  
323 turn into dominant clones in later-stage diseases while unfit subclones are eliminated (Hu  
324 et al., 2019), primarily by the host immune system. In the early phases of carcinogenesis,  
325 stochastic genomic and epigenetic alterations lead to heterogeneous subclones with  
326 various combinations of molecular features that define the distinct biology of each  
327 subclone including survival ability under selective immune pressure. The impact of  
328 genomic and epigenetic alterations on immune response is intertwined. For example,  
329 methylation may directly affect immune response by regulating expression of immune  
330 genes (Liu et al., 2017) or potential neoantigens (Serrano et al., 2011) or indirectly by  
331 increasing DNA vulnerability for development of CNV and somatic mutations that can  
332 subsequently influence the immune microenvironment (Bakhoun and Cantley, 2018;  
333 Porta-Pardo and Godzik, 2016). Global hypomethylation is known to associate with CIN  
334 (Eden et al., 2003) and increased rate of somatic mutations (Chen et al., 1998) and indeed,  
335 global methylation level was negatively associated with TMB and CNV burden in this  
336 cohort of lesions (Hu et al., 2020). Since high CNV burden is associated with a cold

337 immune microenvironment (Davoli et al., 2017) while high TMB can increase tumor  
338 immunogenicity and facilitate immune recognition and elimination of cancer cells (Jung  
339 et al., 2019), the impact of global hypomethylation (associated with both high CNV burden  
340 and TMB) on anti-cancer immunity is further complicated. In the end, the outgrowth of  
341 subclones is determined by the accumulated effects of all molecular aberrations. Only the  
342 cells with the ideal combination of molecular features enabling their rapid proliferation and  
343 escape from immune attack will survive and outgrow into the dominant clones in invasive  
344 cancers. For example, though invasive lung ADCs tend to harbor a high mutation burden  
345 that could lead to more active anti-tumor immune response, they also exhibited a higher  
346 CNV burden, higher likelihood of losing HLA and decreased global methylation, all of  
347 which are associated with a cold tumor immune microenvironment (Jeschke et al., 2017;  
348 Neal et al., 2018; Paulson et al., 2018; Rosenthal et al., 2019), resulting in an overall cold  
349 immune microenvironment in invasive ADCs (lower CD8+ T cell infiltration, CTLs, and T  
350 cell clonality, with higher CD4+ T cell infiltration and Tregs).

351 With the increasing implementation of CT-guided screening and advent of high-resolution  
352 diagnostic CT scans, there has been a drastic increase in the detection of IPNs (Bellomi  
353 et al., 2010; McWilliams et al., 2013), many of which are lung ADC precursors. However,  
354 their management remains controversial. Although surgical resection could potentially  
355 offer cure in a large proportion of these patients, surgery-associated morbidity and high  
356 cost have called surgical resection into question. Additionally, ~25% patients often  
357 present with multifocal diseases, which complicates surgery. We have previously  
358 demonstrated (Hu et al., 2019; Sivakumar et al., 2017) that preinvasive lung ADC  
359 precursors were molecularly simpler, and therefore theoretically easier to eradicate. In



360 the current study, we showed that lung ADC precursors may exhibit an overall better-  
361 preserved anti-tumor immune landscape. In light of these findings, therapeutic strategies  
362 reprogramming the tumor immune microenvironment in patients with lung ADC precursors  
363 prior to further immunosuppression in invasive lung cancers may be beneficial. The lung  
364 cancer immunoprevention clinical trial IMPRINT-Lung (NCT03634241) recruiting  
365 individuals with high-risk IPNs is currently underway to validate this hypothesis.

366

## 367 **ACKNOWLEDGEMENTS**

368 This study was supported by the MD Anderson Khalifa Scholar Award, the National  
369 Cancer Institute of the National Institute of Health Research Project Grant  
370 (R01CA234629-01), the AACR-Johnson & Johnson Lung Cancer Innovation Science  
371 Grant (18-90-52-ZHAN), the MD Anderson Physician Scientist Program, the MD  
372 Anderson Lung Cancer Moon Shot Program, Sabin Family Foundation Award, Duncan  
373 Family Institute Cancer Prevention Research Seed Funding Program, the Cancer  
374 Prevention and Research Institute of Texas Multi-Investigator Research Award grant  
375 (RP160668) and the UT Lung Specialized Programs of Research Excellence Grant  
376 (P50CA70907), Cancer Prevention and Research Institute of Texas (CPRIT) grant  
377 RP150079. We thank Sally Boyd, Jinzhen Chen, and Rong Yao, Eric Sisson and Stan  
378 Bujnowski for providing excellent technical support for high-performance cluster resource  
379 <http://hpcweb.mdanderson.edu/citing.html>. We thank MD Anderson Cancer Center's  
380 Epigenomics Profiling Core and its Science Park Next-Generation Sequencing Core  
381 (supported by CPRIT Core Facility Support Award #RP120348) for performing RRBS  
382 profiling.

383 **AUTHOR CONTRIBUTIONS**

384 J.Z., I.W., H.K., and A.R. conceived, designed, and directed the study. H.D., X.H., R.C.,  
385 J.F., L.L., C.G., C.C., and J.Y. performed the experiments. X.H., Jiexin Z., N.M., S.H.,  
386 J.L., and Jianhua Z. conducted bioinformatic analyses. J.F., E.P., C.H., D.D., L.S., D.S.,  
387 J.F., H.P., B.Z., L.Y., performed pathologic assessment and tissue processing. M.E., M.G.,  
388 M.A., B.S., H.P., C.B., A.V., J.H., P.S., and P.A.F participated in data interpretation and  
389 clinical correlation. J.Z., R.C., H.D., H.K., A.R., and X.H. wrote the manuscript with  
390 comments from all authors.

391

392 **DECLARATION OF INTERESTS**

393 Dr. Zhang reports research funding from Merck, Johnson and Johnson, and consultant  
394 fees from BMS, Johnson and Johnson, AstraZeneca, Geneplus, OrigMed, Innovent  
395 outside the submitted work. The other authors declare no competing financial interests.  
396 Dr. Kadara reports funding form Johnson and Johnson and from Janssen  
397 pharmaceuticals.

398

399 **FIGURE LEGEND**

400 **Figure 1. The immune evolution from preneoplasia to invasive lung**  
401 **adenocarcinoma and associated genomic and epigenomic features.** Infiltration of B  
402 cells, CD4+ T cells, CD8+ T cells inferred from immune gene expression using TIMER;  
403 regulatory T cells (Treg) and activated cytotoxic T lymphocytes (CTL) measured by

404 multiplex immunofluorescence (mIF); T cell clonality and frequency of the top 100 T cell  
405 clones by TCR sequencing are shown in upper panel. Genomic alterations from whole  
406 exome sequencing (WES) including *EGFR/KRAS* mutations, HLA loss, copy number  
407 variation (CNV) burden, allelic imbalance (AI) burden, total number of mutations  
408 associated with predicted neoantigens, total number of mutations associated with  
409 predicted neoantigens without promoter methylation; global methylation status accessed  
410 by reduced representation bisulfite sequencing (RRBS) are shown in bottom panel. AAH:  
411 typical adenomatous hyperplasia. AIS: adenocarcinoma in situ. MIA: minimally invasive  
412 adenocarcinoma. ADC: invasive adenocarcinoma.

413 **Figure 2. Progressively changes of immune cell infiltrations from preneoplasia to**  
414 **invasive lung adenocarcinoma. (A)** Significantly enriched functional pathways based  
415 on the 291 differentially expressed genes by Ingenuity pathway analysis (IPA®; Ingenuity  
416 Systems) software. Pathways with  $-\log(p\text{-value}) > 10$  (p-values are obtained from  
417 Fisher's right-tailed exact test) and an absolute z-score  $> 0.5$  are shown. Pathways that  
418 were predicted to be inhibited (negative Z scores) in later stages are in blue and pathways  
419 that were predicted to be activated (positive Z scores) in later stages are in orange. The  
420 heights of the bars indicate the significance of the enrichment ( $-\log(p\text{-value})$ ) and the  
421 scales of the orange or blue colors represent the predicted directionality. Fractions of  
422 immune cells including CD4+ T cells (**B**), CD8+ T cells (**C**), CD4/CD8 ratio (**D**) and B cells  
423 (**E**) were estimated using TIMER based on the gene expression using nCounter  
424 PanCancer Immune Profiling Panel. Error bars indicate 95% confidence intervals and  
425 solid point represent mean value in each stage. The difference of cell fraction among  
426 different stages was evaluated using the Kruskal-Wallis H test. NL: Normal lung tissue,

427 AAH: Atypical adenomatous hyperplasia, AIS: Adenocarcinoma in situ, MIA: Minimally  
428 invasive adenocarcinoma, ADC: Invasive adenocarcinoma.

429 **Figure 3. Dynamic changes of various immune cells and their interaction with**  
430 **epithelial cells across preneoplasia to invasive lung adenocarcinoma. (A)**

431 Representative multiplex immunofluorescence (mIF) images each histologic stage  
432 analyzed by panel 1 and panel 2 markers. The correlation between immune cell subtypes  
433 and CK+ epithelial cells measured by mIF in AAH (B), AIS (C) and MIA (D). Significant  
434 correlation was marked with \* ( $p < 0.05$ ). Red circles indicate positive correlations and blue  
435 circles indicate negative correlations. The size of circles is proportional to the spearman's  
436 correlation co-efficient between each pair of cells. AAH: Atypical adenomatous  
437 hyperplasia, AIS: Adenocarcinoma in situ, MIA: Minimally invasive adenocarcinoma.

438 **Figure 4. Dynamic change in T cell repertoire from preneoplasia to invasive lung**

439 **adenocarcinoma. T cell diversity (A) and T cell clonality (C) in normal lung, AAH, AIS,**  
440 **MIA and invasive ADC. (B) Distribution of T cell clones with frequency of top 1 (brown),**  
441 **top 2 to 10 (black), top 11 to 100 (orange), top 101 to 200 (purple), top 201 to 500 (green),**  
442 **top 501 to 1000 (red) and beyond 1000 (blue) in normal lung, AAH, AIS, MIA and invasive**  
443 **ADC lesions.**

444

## 445 **STAR METHODS**

### 446 **Patients and tissue processing**

447 Specimens were collected from 53 patients presenting with pulmonary nodules, who  
448 underwent surgical resection at Nagasaki Hospital (Japan) or Zhejiang Cancer Hospital

449 (China) from 2014 to 2017 as described previously (Hu et al., 2019). The study was  
450 approved by the Institutional Review Boards (IRB) at MD Anderson Cancer Center,  
451 Nagasaki University Graduate School of Biomedical Sciences and Zhejiang Cancer  
452 Hospital. Hematoxylin and eosin (HE) slides of each case were reviewed by experienced  
453 lung cancer pathologists to confirm the diagnosis before further analyses.

#### 454 **DNA and RNA extraction**

455 After pathologic assessment, manual macro-dissection was performed to enrich  
456 premalignant cells or cancer cells for DNA or RNA extraction. DNA or RNA was isolated  
457 using the AllPrep® DNA/RNA FFPE Kit (Qiagen, Hilden, Germany) according to  
458 manufacturer's instructions. Finally, the DNA samples were quantified by NanoDrop 1000  
459 Spectrophotometer (Thermo Scientific, Wilmington, DE, USA) and RNA was quantified  
460 using the RNA High sensitivity kit on the Qubit 3.0 fluorometer (Thermo Fisher Scientific,  
461 USA). RNA quality and integrity were evaluated with RNA integrity number (RIN)  
462 (Schroeder et al., 2006), concentration (ng/μl), and size (nt) using RNA Screen Tape in  
463 4200 Tape Station System (Agilent Technologies, USA).

#### 464 **Gene profiling of immune cells using nCounter® platform**

465 The nCounter® PanCancer Immune Profiling Panel (NanoString Technologies, Inc.,  
466 Seattle, WA, USA), which contains 770 genes (including 730 immune associated genes  
467 and 40 housekeeping genes) using NanoString nCounter Analysis was applied for gene  
468 expression profiling as previously described (Cesano, 2015; Kulkarni, 2011). The data  
469 were imported into the nSolver 4.0 software (NanoString Technologies) for quality control  
470 (QC). After the QC was performed with default setting, background correction was done

471 with negative controls, and data was normalized by using the geometric mean of the 6  
472 positive controls, and 40 housekeeping genes. We further performed quantile-  
473 normalization and log<sub>2</sub> transformation to stabilize the variance. A one-way ANOVA test  
474 was applied to identify differentially expressed genes (DEGs) in different stages. We  
475 modeled the p-values using a beta-uniform mixture (BUM) model, combined with false  
476 discovery rate (FDR) to determine a cutoff for p-values (Pounds and Morris, 2003). The  
477 DEGs, along with log ratios were then evaluated with Ingenuity Pathway Analysis (IPA)  
478 software (Quiagen, Hilden, Germany) (Kramer et al., 2014) to identify pathways that are  
479 enriched by these DEGs. We performed a Core Analysis with species set to human and  
480 tissue set to lung. IPA identifies the top canonical pathways associated with the list of  
481 DEGs by the Fisher's exact test to ascertain enrichment. IPA also calculates a z-score to  
482 predict activation status of the pathway by comparing input genes and the stored activity  
483 pattern.

#### 484 **Multiplex immunofluorescence staining**

485 All samples were confirmed to be appropriate for multiplex immunofluorescence (mIF)  
486 analysis based on tissue quality and availability using the HE staining of same lesion by  
487 the experienced pathologist. The manual mIF staining was performed on unstained slides  
488 of FFPE samples using the Opal 7-Color IHC Kit (Akoya Biosciences, USA) as previously  
489 described (Parra et al., 2018). Eight immune markers were placed in two 6-antibody  
490 panels before the stained slides were scanned by Vectra multispectral microscope (Akoya  
491 Biosciences, USA). Panel 1 contained pancytokeratin (AE1/AE3; epithelial marker;  
492 dilution 1:300; Dako, Carpinteria, CA), PD-L1 (clone E1L3N, dilution 1:100; Cell Signaling  
493 Technology, Beverly, MA), PD1 (clone EPR4877-2, dilution 1:250; Abcam, Cambridge,

494 MA), CD3 (T lymphocyte marker; dilution 1:100; Dako), CD8 (cytotoxic T cell marker;  
495 clone C8/144B, dilution 1:20; Thermo Fisher Scientific, Waltham, MA), and CD68  
496 (macrophage marker; clone PG-M1, dilution 1:450; Dako). Panel 2 contained  
497 pancytokeratin, CD3, CD8, CD45RO (memory T cell marker; clone UCHL1, ready to use;  
498 Leica Biosystems, Buffalo Grove, IL), Granzyme B (cytotoxic lymphocyte marker; clone  
499 F1, ready to use; Leica Biosystems), and FoxP3 (regulatory T cell marker; clone 206D,  
500 dilution 1:50; BioLegend, SanDiego, CA). Human tonsil FFPE tissues were used with  
501 each individual antibody on same fluorochrome assay to build the spectral library, and  
502 were also used with and without primary antibodies as positive and negative  
503 (autofluorescence) controls, respectively. The stained slides were scanned with Vectra  
504 3.0 multispectral microscope system (Akoya Biosciences, USA) under fluorescent  
505 illumination. These mIF assays followed our previous publication (Francisco-Cruz et al.,  
506 2020).

### 507 **Multispectral analysis**

508 The five individual fields for multispectral analysis were selected from areas of interest in  
509 a scanned low magnification ( $\times 10$ ) image on Phenochart1.0.9 (Akoya Biosciences, USA).  
510 The five high magnification ( $\times 20$ ) fields for mIF analysis were carefully selected by  
511 experienced pathologists after comparing with HE slides to capture malignant and  
512 premalignant cell cluster and various elements of heterogeneity. The corresponding  
513 normal fields were selected in the farthest field of tumor periphery with morphological  
514 normal tissue on the same slide (**Figure S5A**). The selected high magnification field was  
515 total  $1.6725 \text{ mm}^2$  in size ( $669 \times 500 \mu\text{m}$  per field) (**Figure S5B**). Each field with panel 1 and  
516 panel 2 were overlapped with sequential sections. The target areas were analyzed by in

517 Form 2.4.4 software (Akoya Biosciences, USA). The area was divided into two  
518 compartments: the epithelial compartment (the alveolar wall and septal or malignant cell  
519 nests) and alveolar air space or tumor stroma compartment (**Figure S5C**). The individual  
520 cells were recognized by DAPI nuclei staining (**Figure S5D**). Panel 1 contained the co-  
521 localization patterns as follows: PD-L1 expressing CK+ cells (CK+PD-L1+), total T  
522 lymphocytes (total CD3+), cytotoxic T lymphocytes (CD3+CD8+), antigen experienced T  
523 lymphocytes (CD3+PD-1), antigen experienced cytotoxic T lymphocytes (CD3+CD8+PD-  
524 1+), total macrophages (total CD68+), and PD-L1 expressing macrophages (CD68+ PD-  
525 L1+). Panel 2 contained the co-localization patterns as follows: total T lymphocytes (total  
526 CD3+), cytotoxic T lymphocytes (CD3+CD8+), activated cytotoxic T lymphocytes  
527 (CD3+CD8+GB+), memory T lymphocytes (CD3+CD45RO+), effector/memory T  
528 lymphocytes (CD3+CD8+CD45RO+), regulatory T lymphocytes (CD3+FOXP3+CD8-),  
529 and memory/regulatory T lymphocytes (CD3+CD45RO+FOXP3+) (**Figure S5**). The  
530 percentage of the total nucleated cell density from each individual cell phenotyping  
531 population was used for further analysis.

### 532 **TCR $\beta$ amplification and sequencing**

533 Immunosequencing of the CDR3 regions of human TCR $\beta$  chains was performed using  
534 the protocol of ImmunoSeq (Adaptive Biotechnologies, hsTCR $\beta$  Kit) and T cell clonality  
535 and diversity were calculated as described previously (Reuben et al., 2017; Reuben et  
536 al., 2020).

537 Briefly, T cell clonality is a metric of T cell proliferation and reactivity, and it is defined as  
538 1-Pielou's evenness and is calculated on productive rearrangements by:



$$1 + \frac{\sum_{i=1}^N p_i \log_2(p_i)}{\log_2(N)}$$

539  
540 Where  $p_i$  is the proportional abundance of rearrangement  $i$ , and  $N$  is the total number of  
541 rearrangements. Clonality ranges from 0 to 1: values approaching 0 indicate a very even  
542 distribution frequency of different clones (polyclonal), whereas values approaching 1  
543 indicate a distinct asymmetric distribution in which a few activated clones are present at  
544 high frequencies (monoclonal).

545 We also applied Inverse Simpson in order to observe T cell diversity, the sum over all  
546 observed rearrangements of the square fractional abundances of each rearrangements  
547 using productive templates.

$$\frac{1}{\sum_{i=1}^S p_i^2}$$

550 Where  $p_i$  is the proportional abundance of rearrangement  $i$ , and  $S$  is the total number of  
551 rearrangements. Inverse Simpson ranges from 1 to infinite, where a sample with little  
552 variation or abundance has a value approaching 1, and a maximally diverse and evenly  
553 distributed sample has a value approaching infinite.

#### 554 **Analysis of genomic and methylation profiling data**

555 Genomic and methylation data were generated and processed in previous studies as  
556 described (Hu et al., 2020; Hu et al., 2019). Somatic mutations, allelic imbalance (AI),  
557 copy number variations (CNV), oncogene mutations, global methylation data were

558 directed from above mentioned studies. The following additional analyses were  
559 performed on the genomic data.

### 560 **Detection of allele-specific HLA loss**

561 Class I HLA alleles for each HLA gene was inferred by POLYSOLVER using a two-step  
562 Bayesian classification approach (Shukla et al., 2015). This approach takes into account  
563 the base qualities of aligned reads, observed insert sizes, as well as the ethnicity-  
564 dependent prior probabilities of each allele (Shukla et al., 2015). Tumor purity and ploidy  
565 were estimated using ASCAT (Van Loo et al., 2010). We then applied LOHHLA (Loss Of  
566 Heterozygosity in Human Leukocyte Antigen) algorithm (McGranahan et al., 2017) to  
567 detect allele-specific HLA loss in each sample. In brief, logR and BAF across each HLA  
568 gene loci was obtained by binning the coverage at mismatch positions between  
569 homologous HLA alleles, and HLA haplotype specific copy numbers were then calculated  
570 based on logR and BAF value from the corresponding bin adjusted by tumor purity and  
571 ploidy. The median value of binned allelic copy number was used to determined LOH,  
572 where a copy number of  $< 0.5$  indicated allele loss and AI was determined if  $p < 0.01$ .

### 573 **Statistical Analysis**

574 Different statistical models were applied to assess the association among immune data,  
575 genomic data and methylation data. When assessing association between two variables,  
576 different tests were applied depending on the types of variables. For association between  
577 two continuous variables, spearman's rank correlation test was used. For association  
578 between one continuous variable and one categorical variable, Wilcoxon rank-sum test  
579 (categorical variable with two levels) and Kruskal-Wallis test (categorical variable with

580 more than two levels) were applied. The FDR method was used for multiple testing  
581 adjustment of p-values (Benjamini and Hochberg, 1995). All p-values are calculated with  
582 two-sided test, and  $p < 0.05$  was considered to be statistically significant.

### 583 **DATA AVAILABILITY**

584 The data from WES has been deposited at European Genome-phenome Archive (EGA),  
585 which is hosted by The European Bioinformatics Institute (EBI) and the Centre for  
586 Genomic Regulation (CRG) under the accession code: EGAS00001004960  
587 [<https://www.ebi.ac.uk/ega/datasets/EGAD00001004960>]. All other data may be found  
588 within the main manuscript or supplementary Information or available from the authors  
589 upon request.

590

591

592 **SUPPLEMENTAL INFORMATION**

593 **SUPPLEMENTAL FIGURE LEGENDS**

594 **Figure S1. Example genes differentially expressed from preneoplasia to invasive**  
595 **lung adenocarcinoma.** Gene expression of *CD47* (A), *CD276* (B), *CTLA4* (C), *ENTPD1*  
596 (D), *GZMB* (E), *PRF1* (F) was performed using the nCounter PanCancer Immune Profiling  
597 Panel (Nanostring). The difference in expression of each gene among different stages  
598 was evaluated using the Kruskal-Wallis H test. AAH: typical adenomatous hyperplasia.  
599 AIS: adenocarcinoma in situ. MIA: minimally invasive adenocarcinoma. ADC: invasive  
600 adenocarcinoma.

601 **Figure S2. Expression of tertiary lymphoid structure (TLS) marker genes from**  
602 **preneoplasia to invasive lung adenocarcinoma.** Gene expression of B cell marker  
603 *CD19* (A) and *MS4A1* (*CD20*) (B); follicle formation markers *CXCL13* (C) and *CXCR5*  
604 (D); T lymphocyte homing markers *CCL19* (E) and *CCR7* (F) was performed using the  
605 nCounter PanCancer Immune Profiling Panel (Nanostring). The difference in expression  
606 of each gene among different stages was evaluated using the Kruskal-Wallis H test. AAH:  
607 typical adenomatous hyperplasia. AIS: adenocarcinoma in situ. MIA: minimally invasive  
608 adenocarcinoma. ADC: invasive adenocarcinoma.

609 **Figure S3. Expression of TLS marker genes was associated with B cells, CD4+**  
610 **lymphocytes and CD8+ lymphocytes.** Gene expression profiling was performed using  
611 the nCounter PanCancer Immune Profiling Panel (Nanostring). Infiltration of B cells,  
612 CD4+ T cells and CD8+ T cells was estimated using TIMER based on the gene  
613 expression using nCounter PanCancer Immune Profiling Panel. The association between

614 the expression of each TLS marker gene and B cells, CD4+ T cells and CD8+ T cells  
615 were evaluated using xxx test.

616 **Figure S4. Progressively changes of immune cell in filtration normal lung,**  
617 **preneoplasia and invasive lung adenocarcinoma.** Immune cell fractions including  
618 CD4+ T cells (**A**), CD8+ T cells (**B**), CD4 /CD8 ratio (**C**), B cells (**D**) were estimated using  
619 TIMER based on previously published RNA sequencing data from an independent cohort  
620 (GSE102511). Error bars indicate 95% confidence intervals and solid point represent  
621 mean value in each stage. The difference of cell fraction among stages was evaluated  
622 using the Kruskal-Wallis H test. NL: Normal lung tissue, AAH: Atypical adenomatous  
623 hyperplasia, ADC: Invasive adenocarcinoma.

624 **Figure S5. Quantitative image analysis of multiplex immunofluorescence image**  
625 **data.** (**A**) After immunofluorescent staining, high magnification fields of interest were  
626 selected in both malignant (pre-malignant) and non-malignant regions. The non-malignant  
627 fields at the farthest regions from malignant (pre-malignant) regions with morphologically  
628 normal histology were selected. (**B**) Representative images from Panel 1 and Panel 2. (**C**)  
629 The selected fields were divided into two areas: epithelium and alveolar space. (**D**)  
630 Individual cells were recognized by DAPI (nuclear staining).

631 **Figure S6. Subtyping immune and epithelial cells by multiplex**  
632 **immunofluorescence.** Cell subtypes were defined as PD-L1 expressing epithelial cells  
633 (AE1/AE3+PD-L1+), T lymphocytes (CD3+), antigen-experienced T cells (CD3+PD-1+),  
634 cytotoxic T lymphocytes (CTL, CD3+CD8+), antigen-experienced CTL (CD3+CD8+PD-  
635 1+), macrophages (CD68+) and PD-L1 expressing macrophages (CD68+PD-L1+) in  
636 panel 1 (left); and activated CTL (CD3+CD8+granzyme B+), memory T cell

637 (CD3+CD45RO+), memory CTL (CD3+CD8+CD45RO+), regulatory T cell (CD3+CD8-  
638 FoxP3+), memory/regulatory T cell (CD3+CD45RO+FoxP3+) in panel 2 (right).

639 **Figure S7. The correlation between immune cell subtypes measured by multiplex  
640 immunofluorescence and T cell subtypes inferred from immune gene expression.**

641 Fractions of immune cells including CD8+ T cells (**A**), CD4+ T cells (**B**) and CD4/CD8  
642 ratio (**C**) estimated using TIMER based on the gene expression from nCounter  
643 PanCancer Immune Profiling Panel (y-axis) were correlated to activated CTL  
644 (CD3+CD8+granzyme B+), regulatory T cell (CD3+CD8-FoxP3+) and Treg/activated CTL  
645 ratio respectively (x-axis). All fraction and ratio were log<sub>2</sub> transformed for visualization.  
646 The correlation coefficient ( $\rho$ ) was assessed by Spearman's rank correlation test.

647 **Figure S8. Various subtypes immune cells and their interaction with epithelial cells  
648 in normal lung tissues and invasive lung adenocarcinoma.** The correlation between

649 immune cell subtypes and CK+ epithelial cells measured by mIF in normal lung (**A**) and  
650 invasive lung adenocarcinoma (**B**). Significant correlation was marked with \* ( $p < 0.05$ ).  
651 Red circles indicate positive correlations and blue circles indicate negative correlations.  
652 The size of circles is proportional to the spearman's correlation co-efficient between each  
653 pair of cells. ADC: Invasive adenocarcinoma.

654 **Figure S9. Correlation between T cell diversity and regulatory T cells.** T cell diversity

655 was positively correlated with infiltration of CD4+ T cells derived from immune gene  
656 expression using TIMER (**A**), regulatory T cells from multiplex immunofluorescence (mIF)  
657 (**B**). The correlation coefficient ( $\rho$ ) was assessed by Spearman's rank correlation test.

658 **Figure S10. Progressive decrease of top T cell clone frequencies from preneoplasia**  
659 **to invasive lung adenocarcinoma.** Frequencies of (A) top 10, (B) top 100, (C) top 200  
660 and (D) top 500 T cell clones in the Normal (yellow), AAH (blue), AIS (red), MIA (green)  
661 and ADC (purple). The difference between different stages were assessed by the Kruskal-  
662 Wallis H test.

663 **Figure S11. Correlation between T cell clonality and different T cell subtypes.** T cell  
664 clonality was positively correlated with infiltration of CD8+ T cells inferred from gene  
665 expression by TIMER (A), activated cytotoxic T cells (B) by mIF, expression of GZBM (C)  
666 and Th1 cytokines (INFG, IL12A and IL12B) (D) but negative correlated with infiltration of  
667 CD4+ T cells derived from gene expression by TIMER (E) and regulatory T cells by mIF  
668 (F). The correlation coefficient ( $\rho$ ) was assessed by Spearman's rank correlation test.

669 **Figure S12. The impact of oncogene mutations on T cell features.** Comparison of  
670 infiltration of CD8+ T cells inferred from gene expression by TIMER (A), cytotoxic T cells  
671 (CTL) (B) by mIF, CD4/CD8 ratio inferred from gene expression by TIMER (C), Effector  
672 memory cytotoxic T cells by mIF (D), CTL/Treg ratio (E) by mIF, T cell clonality by TCR  
673 sequencing (F) in lesions with *EGFR* mutation (pink), *KRAS* mutation (orange) and  
674 wildtype for both *KRAS* and *EGFR* (green). The difference was assessed by Wilcoxon-rank  
675 sum test.

676 **Figure S13. The impact of oncogene mutations on T cell features by different**  
677 **histologic stages.** Comparison of infiltration of CD8+ T cells inferred from gene  
678 expression by TIMER (A), cytotoxic T cells (CTL) (B) by mIF, CD4/CD8 ratio inferred from  
679 gene expression by TIMER (C), Effector memory cytotoxic T cells by mIF (D), CTL/Treg  
680 ratio (E) by mIF, T cell clonality by TCR sequencing (F) in lesions with *EGFR* mutation

681 (pink), *KRAS* mutation (orange) and wildtype for both *KRAS* and *EGFR* (green) in AAH,  
682 AIS, MIA and ADC. The difference was assessed by Wilcoxon-rank sum test. AAH: Atypical  
683 adenomatous hyperplasia, AIS: Adenocarcinoma in situ, MIA: Minimally invasive  
684 adenocarcinoma, ADC: Invasive adenocarcinoma.

685 **Figure S14. Loss of heterozygosity of HLA (HLA LOH) in different histologic stages**  
686 **from preneoplasia to invasive lung adenocarcinoma and its potential impact on**  
687 **immune contexture. (A)** The proportion of AAH, AIS, MIA and ADC lesions had evidence  
688 of HLA-LOH. Chi-squared test were used to assess the difference among different  
689 histologic stages. The difference of infiltration of CD4+ T cells (**B**), CD8+ T cells (**C**) and  
690 CD4/CD8 ratio (**D**) inferred from gene expression by TIMER between lesions with (purple)  
691 and without (green) HLA-LOH.

692 **Figure S15. The potential impact of chromosomal copy number changes on**  
693 **immune infiltration.** The correlation between allelic imbalance (AI) burden (number of  
694 AI events) and infiltration of CD4+ T cells (**A**), CD8+ T cells (**B**), CD4/CD8 ratio (**C**)  
695 inferred from gene expression by TIMER. The correlation between copy number variation  
696 (CNV) burden (normalized as the number of genes with CNV) and infiltration of CD4+ T  
697 cells (**D**), CD8+ T cells (**E**), CD4/CD8 ratio (**F**) inferred from gene expression by TIMER.  
698 The correction coefficient ( $\rho$ ) was assessed by Spearman's rank correlation test.

699 **Figure S16. The relationship between HLA loss and chromosomal copy number**  
700 **variations. (A)** Comparison of allelic imbalance (AI) burden (number of AI events) in  
701 lesions with (purple) and without (green) HLA-LOH. (**B**) Comparison of copy number  
702 variation (CNV) burden (normalized as the percent of genes with CNV) in lesions with



703 (purple) and without (green) HLA-LOH. Willcoxon rank-sum test was used to assess the  
704 differences.

705 **Figure S17. Promoter methylation and mutation burden from preneoplasia to**  
706 **invasive lung adenocarcinoma.** The number of all nonsynonymous mutations in each  
707 histologic stage is shown as purple boxes and the number of nonsynonymous mutations  
708 from genes without promoter methylation (<30% CpG sites methylated) is shown as blue  
709 boxes.

710 **Figure S18. The potential impact of global methylation and immune infiltration.** The  
711 correlation between global methylation levels (using LINE-1 as a surrogate marker) with  
712 CD4+ T cells (**A**), CD4/CD8 ratio (**B**) inferred from immune gene expression by TIMER  
713 as well as Tregs (**C**) and Treg/CD8 ratio (**D**) measured by mIF. The correlation coefficient  
714 ( $\rho$ ) was assessed by Spearman's rank correlation test.

## 715 **SUPPLEMENTAL TABLES**

716 **Table S1. Clinical characteristics and availability of different immune and molecular**  
717 **data**

718 **Table S2. Statistics of Differentially Expressed Genes**

719

720

## 721 REFERENCES

- 722 Aoyagi, Y., Yokose, T., Minami, Y., Ochiai, A., Iijima, T., Morishita, Y., Oda, T., Fukao, K., and Noguchi, M.  
723 (2001). Accumulation of losses of heterozygosity and multistep carcinogenesis in pulmonary  
724 adenocarcinoma. *Cancer research* *61*, 7950-7954.
- 725 Bakhom, S. F., and Cantley, L. C. (2018). The Multifaceted Role of Chromosomal Instability in Cancer  
726 and Its Microenvironment. *Cell* *174*, 1347-1360.
- 727 Barnett, R. (2017). Lung cancer. *The Lancet* *390*, 928.
- 728 Bastid, J., Cottalorda-Regairaz, A., Alberici, G., Bonnefoy, N., Eliaou, J., and Bensussan, A. (2013).  
729 ENTPD1/CD39 is a promising therapeutic target in oncology. *Oncogene* *32*, 1743-1751.
- 730 Bellomi, M., Veronesi, G., Trifirò, G., Brambilla, S., Bonello, L., Preda, L., Casiraghi, M., Borri, A., Paganelli,  
731 G., and Spaggiari, L. (2010). Computed tomography-guided preoperative radiotracer localization of  
732 nonpalpable lung nodules. *The Annals of thoracic surgery* *90*, 1759-1764.
- 733 Benjamini, Y., and Hochberg, Y. (1995). Controlling the False Discovery Rate - a Practical and Powerful  
734 Approach to Multiple Testing. *J R Stat Soc B* *57*, 289-300.
- 735 Borghaei, H., Paz-Ares, L., Horn, L., Spigel, D. R., Steins, M., Ready, N. E., Chow, L. Q., Vokes, E. E., Felip,  
736 E., Holgado, E., *et al.* (2015). Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell  
737 Lung Cancer. *N Engl J Med* *373*, 1627-1639.
- 738 Cabrita, R., Lauss, M., Sanna, A., Donia, M., Larsen, M. S., Mitra, S., Johansson, I., Phung, B., Harbst, K.,  
739 and Vallon-Christersson, J. (2020). Tertiary lymphoid structures improve immunotherapy and survival in  
740 melanoma. *Nature* *577*, 561-565.
- 741 Cesano, A. (2015). nCounter® PanCancer Immune Profiling Panel (NanoString Technologies, Inc.,  
742 Seattle, WA). *Journal for immunotherapy of cancer* *3*, 42.
- 743 Chen, P. L., Roh, W., Reuben, A., Cooper, Z. A., Spencer, C. N., Prieto, P. A., Miller, J. P., Bassett, R. L.,  
744 Gopalakrishnan, V., Wani, K., *et al.* (2016). Analysis of Immune Signatures in Longitudinal Tumor Samples  
745 Yields Insight into Biomarkers of Response and Mechanisms of Resistance to Immune Checkpoint  
746 Blockade. *Cancer Discov* *6*, 827-837.
- 747 Chen, R. Z., Pettersson, U., Beard, C., Jackson-Grusby, L., and Jaenisch, R. (1998). DNA hypomethylation  
748 leads to elevated mutation rates. *Nature* *395*, 89-93.
- 749 Chiosea, S., Jelezcova, E., Chandran, U., Luo, J., Mantha, G., Sobol, R. W., and Dacic, S. (2007).  
750 Overexpression of Dicer in precursor lesions of lung adenocarcinoma. *Cancer research* *67*, 2345-2350.
- 751 Davoli, T., Uno, H., Wooten, E. C., and Elledge, S. J. (2017). Tumor aneuploidy correlates with markers of  
752 immune evasion and with reduced response to immunotherapy. *Science* *355*.
- 753 de Koning, H. J., van der Aalst, C. M., de Jong, P. A., Scholten, E. T., Nackaerts, K., Heuvelmans, M. A.,  
754 Lammers, J.-W. J., Weenink, C., Yousaf-Khan, U., and Horeweg, N. (2020). Reduced lung-cancer mortality  
755 with volume CT screening in a randomized trial. *New England Journal of Medicine* *382*, 503-513.
- 756 Dunn, G. P., Bruce, A. T., Ikeda, H., Old, L. J., and Schreiber, R. D. (2002). Cancer immunoediting: from  
757 immunosurveillance to tumor escape. *Nature immunology* *3*, 991-998.
- 758 Dunn, G. P., Old, L. J., and Schreiber, R. D. (2004a). The immunobiology of cancer immunosurveillance  
759 and immunoediting. *Immunity* *21*, 137-148.
- 760 Dunn, G. P., Old, L. J., and Schreiber, R. D. (2004b). The three Es of cancer immunoediting. *Annu Rev*  
761 *Immunol* *22*, 329-360.
- 762 Eden, A., Gaudet, F., Waghmare, A., and Jaenisch, R. (2003). Chromosomal instability and tumors  
763 promoted by DNA hypomethylation. *Science* *300*, 455.
- 764 Francisco-Cruz, A., Parra, E. R., Tetzlaff, M. T., and Wistuba, II (2020). Multiplex Immunofluorescence  
765 Assays. *Methods in molecular biology (Clifton, NJ)* *2055*, 467-495.
- 766 Fridman, W. H., Zitvogel, L., Sautès-Fridman, C., and Kroemer, G. (2017). The immune contexture in  
767 cancer prognosis and treatment. *Nature reviews Clinical oncology* *14*, 717.

768 Hu, X., Estecio, M. R., Chen, R., Reuben, A., Wang, L., Junya, F., Ying, L., Junya, F., Chow, C.-W.,  
769 McGranahan, N., *et al.* (2020). Evolution of the DNA methylome from precancer to invasive lung  
770 adenocarcinoma. medRxiv, 2020.2007.2011.20142745.

771 Hu, X., Fujimoto, J., Ying, L., Fukuoka, J., Ashizawa, K., Sun, W., Reuben, A., Chow, C.-W., McGranahan,  
772 N., and Chen, R. (2019). Multi-region exome sequencing reveals genomic evolution from preneoplasia to  
773 lung adenocarcinoma. *Nature communications* 10, 2978.

774 Izumchenko, E., Chang, X., Brait, M., Fertig, E., Kagohara, L. T., Bedi, A., Marchionni, L., Agrawal, N., Ravi,  
775 R., Jones, S., *et al.* (2015). Targeted sequencing reveals clonal genetic changes in the progression of early  
776 lung neoplasms and paired circulating DNA. *Nature communications* 6, 8258.

777 Jeschke, J., Bizet, M., Desmedt, C., Calonne, E., Dedeurwaerder, S., Garaud, S., Koch, A., Larsimont, D.,  
778 Salgado, R., and Van den Eynden, G. (2017). DNA methylation–based immune response signature  
779 improves patient diagnosis in multiple cancers. *The Journal of clinical investigation* 127, 3090-3102.

780 Jung, H., Kim, H. S., Kim, J. Y., Sun, J. M., Ahn, J. S., Ahn, M. J., Park, K., Esteller, M., Lee, S. H., and Choi, J.  
781 K. (2019). DNA methylation loss promotes immune evasion of tumours with high mutation and copy  
782 number load. *Nat Commun* 10, 4278.

783 Kankava, K., Kvaratskhelia, E., Burkadze, G., Kokhreidze, I., Gogokhia, N., and Abzianidze, E. (2018). Line-  
784 1 Methylation in Blood and Tissues of Patients with Breast Cancer. *Georgian Med News*, 107-112.

785 Kaplinsky, J., and Arnaout, R. (2016). Robust estimates of overall immune-repertoire diversity from high-  
786 throughput measurements on samples. *Nature communications* 7, 11881-11881.

787 Kitamura, H., Kameda, Y., Ito, T., and Hayashi, H. (1999). Atypical adenomatous hyperplasia of the lung:  
788 implications for the pathogenesis of peripheral lung adenocarcinoma. *American journal of clinical*  
789 *pathology* 111, 610-622.

790 Kramer, A., Green, J., Pollard, J., Jr., and Tugendreich, S. (2014). Causal analysis approaches in Ingenuity  
791 Pathway Analysis. *Bioinformatics (Oxford, England)* 30, 523-530.

792 Kulkarni, M. M. (2011). Digital multiplexed gene expression analysis using the NanoString nCounter  
793 system. *Current protocols in molecular biology Chapter 25*, Unit25B.10.

794 Lavin, Y., Kobayashi, S., Leader, A., Amir, E.-a. D., Elefant, N., Bigenwald, C., Remark, R., Sweeney, R.,  
795 Becker, C. D., Levine, J. H., *et al.* Innate Immune Landscape in Early Lung Adenocarcinoma by Paired  
796 Single-Cell Analyses. *Cell* 169, 750-765.e717.

797 Li, T., Fu, J., Zeng, Z., Cohen, D., Li, J., Chen, Q., Li, B., and Liu, X. S. (2020). TIMER2.0 for analysis of  
798 tumor-infiltrating immune cells. *Nucleic acids research*.

799 Liu, M., Zhou, J., Chen, Z., and Cheng, A. S. (2017). Understanding the epigenetic regulation of tumours  
800 and their microenvironments: opportunities and problems for epigenetic therapy. *J Pathol* 241, 10-24.

801 Maeshima, A. M., Tochigi, N., Yoshida, A., Asamura, H., Tsuta, K., and Tsuda, H. (2010). Clinicopathologic  
802 analysis of multiple (five or more) atypical adenomatous hyperplasias (AAHs) of the lung: evidence for  
803 the AAH-adenocarcinoma sequence. *Journal of thoracic oncology : official publication of the*  
804 *International Association for the Study of Lung Cancer* 5, 466-471.

805 Mansfield, A. S., Ren, H., Sutor, S., Sarangi, V., Nair, A., Davila, J., Elsbernd, L. R., Udell, J. B., Dronca, R. S.,  
806 Park, S., *et al.* (2018). Contraction of T cell richness in lung cancer brain metastases. *Scientific reports* 8,  
807 2171.

808 Mascaux, C., Angelova, M., Vasaturo, A., Beane, J., Hijazi, K., Anthoine, G., Buttard, B., Rothe, F., Willard-  
809 Gallo, K., Haller, A., *et al.* (2019). Immune evasion before tumour invasion in early lung squamous  
810 carcinogenesis. *Nature* 571, 570-575.

811 McGranahan, N., Furness, A. J., Rosenthal, R., Ramskov, S., Lyngaa, R., Saini, S. K., Jamal-Hanjani, M.,  
812 Wilson, G. A., Birkbak, N. J., Hiley, C. T., *et al.* (2016). Clonal neoantigens elicit T cell immunoreactivity  
813 and sensitivity to immune checkpoint blockade. *Science* 351, 1463-1469.

814 McGranahan, N., Rosenthal, R., Hiley, C. T., Rowan, A. J., Watkins, T. B. K., Wilson, G. A., Birkbak, N. J.,  
815 Veeriah, S., Van Loo, P., Herrero, J., *et al.* (2017). Allele-Specific HLA Loss and Immune Escape in Lung  
816 Cancer Evolution. *Cell* *171*, 1259-1271.e1211.

817 McWilliams, A., Tammemagi, M. C., Mayo, J. R., Roberts, H., Liu, G., Soghrati, K., Yasufuku, K., Martel, S.,  
818 Laberge, F., and Gingras, M. (2013). Probability of cancer in pulmonary nodules detected on first  
819 screening CT. *New England Journal of Medicine* *369*, 910-919.

820 Min, J. H., Lee, H. Y., Lee, K. S., Han, J., Park, K., Ahn, M. J., and Lee, S. J. (2010). Stepwise evolution from  
821 a focal pure pulmonary ground-glass opacity nodule into an invasive lung adenocarcinoma: an  
822 observation for more than 10 years. *Lung cancer (Amsterdam, Netherlands)* *69*, 123-126.

823 Mittal, D., Gubin, M. M., Schreiber, R. D., and Smyth, M. J. (2014). New insights into cancer  
824 immunoediting and its three component phases—elimination, equilibrium and escape. *Current opinion*  
825 *in immunology* *27*, 16-25.

826 Neal, J. T., Li, X., Zhu, J., Giangarra, V., Grzeskowiak, C. L., Ju, J., Liu, I. H., Chiou, S.-H., Salahudeen, A. A.,  
827 and Smith, A. R. (2018). Organoid modeling of the tumor immune microenvironment. *Cell* *175*, 1972-  
828 1988. e1916.

829 Noguchi, M. (2010). Stepwise progression of pulmonary adenocarcinoma—clinical and molecular  
830 implications. *Cancer and Metastasis Reviews* *29*, 15-21.

831 O'Donnell, J. S., Teng, M. W., and Smyth, M. J. (2019). Cancer immunoediting and resistance to T cell-  
832 based immunotherapy. *Nature reviews Clinical oncology* *16*, 151-167.

833 Ohka, F., Natsume, A., Motomura, K., Kishida, Y., Kondo, Y., Abe, T., Nakasu, Y., Namba, H., Wakai, K.,  
834 Fukui, T., *et al.* (2011). The global DNA methylation surrogate LINE-1 methylation is correlated with  
835 MGMT promoter methylation and is a better prognostic factor for glioma. *PLoS One* *6*, e23332.

836 Pan, L., Lu, M. P., Wang, J. H., Xu, M., and Yang, S. R. (2020). Immunological pathogenesis and treatment  
837 of systemic lupus erythematosus. *World J Pediatr* *16*, 19-30.

838 Pantelidou, C., Sonzogni, O., De Oliveria Taveira, M., Mehta, A. K., Kothari, A., Wang, D., Visal, T., Li, M.  
839 K., Pinto, J., Castrillon, J. A., *et al.* (2019). PARP Inhibitor Efficacy Depends on CD8(+) T-cell Recruitment  
840 via Intratumoral STING Pathway Activation in BRCA-Deficient Models of Triple-Negative Breast Cancer.  
841 *Cancer Discov* *9*, 722-737.

842 Pardoll, D. M. (2012). The blockade of immune checkpoints in cancer immunotherapy. *Nature Reviews*  
843 *Cancer* *12*, 252-264.

844 Parra, E. R., Villalobos, P., Behrens, C., Jiang, M., Pataer, A., Swisher, S. G., William, W. N., Jr., Zhang, J.,  
845 Lee, J., Cascone, T., *et al.* (2018). Effect of neoadjuvant chemotherapy on the immune  
846 microenvironment in non-small cell lung carcinomas as determined by multiplex immunofluorescence  
847 and image analysis approaches. *J Immunother Cancer* *6*, 48.

848 Paulson, K., Voillet, V., McAfee, M., Hunter, D., Wagener, F., Perdicchio, M., Valente, W., Koelle, S.,  
849 Church, C., and Vandeven, N. (2018). Acquired cancer resistance to combination immunotherapy from  
850 transcriptional loss of class I HLA. *Nature communications* *9*, 1-10.

851 Picarda, E., Ohaegbulam, K. C., and Zang, X. (2016). Molecular pathways: targeting B7-H3 (CD276) for  
852 human cancer immunotherapy. *Clinical Cancer Research* *22*, 3425-3431.

853 Porta-Pardo, E., and Godzik, A. (2016). Mutation Drivers of Immunological Responses to Cancer. *Cancer*  
854 *Immunol Res* *4*, 789-798.

855 Pounds, S., and Morris, S. W. (2003). Estimating the occurrence of false positives and false negatives in  
856 microarray studies by approximating and partitioning the empirical distribution of p-values.  
857 *Bioinformatics* *19*, 1236-1242.

858 Prakash, M. D., Munoz, M. A., Jain, R., Tong, P. L., Koskinen, A., Regner, M., Kleinfeld, O., Ho, B., Olson,  
859 M., and Turner, S. J. (2014). Granzyme B promotes cytotoxic lymphocyte transmigration via basement  
860 membrane remodeling. *Immunity* *41*, 960-972.

861 Reuben, A., Gittelman, R., Gao, J., Zhang, J., Yusko, E. C., Wu, C. J., Emerson, R., Zhang, J., Tipton, C., Li, J.,  
862 *et al.* (2017). TCR Repertoire Intratumor Heterogeneity in Localized Lung Adenocarcinomas: An  
863 Association with Predicted Neoantigen Heterogeneity and Postsurgical Recurrence. *Cancer Discov* 7,  
864 1088-1097.

865 Reuben, A., Zhang, J., Chiou, S. H., Gittelman, R. M., Li, J., Lee, W. C., Fujimoto, J., Behrens, C., Liu, X.,  
866 Wang, F., *et al.* (2020). Comprehensive T cell repertoire characterization of non-small cell lung cancer.  
867 *Nat Commun* 11, 603.

868 Rosenthal, R., Cadieux, E. L., Salgado, R., Al Bakir, M., Moore, D. A., Hiley, C. T., Lund, T., Tanić, M.,  
869 Reading, J. L., and Joshi, K. (2019). Neoantigen-directed immune escape in lung cancer evolution. *Nature*  
870 567, 479-485.

871 Saito, K., Kawakami, K., Matsumoto, I., Oda, M., Watanabe, G., and Minamoto, T. (2010). Long  
872 interspersed nuclear element 1 hypomethylation is a marker of poor prognosis in stage IA non-small cell  
873 lung cancer. *Clin Cancer Res* 16, 2418-2426.

874 Schreiber, R. D., Old, L. J., and Smyth, M. J. (2011). Cancer immunoeediting: integrating immunity's roles  
875 in cancer suppression and promotion. *Science* 331, 1565-1570.

876 Schroeder, A., Mueller, O., Stocker, S., Salowsky, R., Leiber, M., Gassmann, M., Lightfoot, S., Menzel, W.,  
877 Granzow, M., and Ragg, T. (2006). The RIN: an RNA integrity number for assigning integrity values to  
878 RNA measurements. *BMC molecular biology* 7, 3.

879 Seki, M., and Akasaka, Y. (2007). Multiple lung adenocarcinomas and AAH treated by surgical resection.  
880 *Lung cancer (Amsterdam, Netherlands)* 55, 237-240.

881 Serrano, A., Castro-Vega, I., and Redondo, M. (2011). Role of gene methylation in antitumor immune  
882 response: implication for tumor progression. *Cancers (Basel)* 3, 1672-1690.

883 Shah, W., Yan, X., Jing, L., Zhou, Y., Chen, H., and Wang, Y. (2011). A reversed CD4/CD8 ratio of tumor-  
884 infiltrating lymphocytes and a high percentage of CD4+ FOXP3+ regulatory T cells are significantly  
885 associated with clinical outcome in squamous cell carcinoma of the cervix. *Cellular & molecular*  
886 *immunology* 8, 59-66.

887 Shukla, S. A., Rooney, M. S., Rajasagi, M., Tiao, G., Dixon, P. M., Lawrence, M. S., Stevens, J., Lane, W. J.,  
888 Dellagatta, J. L., Steelman, S., *et al.* (2015). Comprehensive analysis of cancer-associated somatic  
889 mutations in class I HLA genes. *Nature biotechnology* 33, 1152-1158.

890 Siegel, R. L., Miller, K. D., and Jemal, A. (2020). Cancer statistics, 2020. *CA Cancer J Clin* 70, 7-30.

891 Sivakumar, S., Lucas, F. A. S., McDowell, T. L., Lang, W., Xu, L., Fujimoto, J., Zhang, J., Futreal, P. A.,  
892 Fukuoka, J., Yatabe, Y., *et al.* (2017). Genomic Landscape of Atypical Adenomatous Hyperplasia Reveals  
893 Divergent Modes to Lung Adenocarcinoma. *Cancer research* 77, 6119-6130.

894 Soto-Pantoja, D. R., Terabe, M., Ghosh, A., Ridnour, L. A., DeGraff, W. G., Wink, D. A., Berzofsky, J. A.,  
895 and Roberts, D. D. (2014). CD47 in the tumor microenvironment limits cooperation between antitumor  
896 T-cell immunity and radiotherapy. *Cancer research* 74, 6771-6783.

897 Tan, W. L., Jain, A., Takano, A., Newell, E. W., Iyer, N. G., Lim, W. T., Tan, E. H., Zhai, W., Hillmer, A. M.,  
898 Tam, W. L., and Tan, D. S. W. (2016). Novel therapeutic targets on the horizon for lung cancer. *The*  
899 *Lancet Oncology* 17, e347-e362.


900 Thorsson, V., Gibbs, D. L., Brown, S. D., Wolf, D., Bortone, D. S., Yang, T.-H. O., Porta-Pardo, E., Gao, G. F.,  
901 Plaisier, C. L., and Eddy, J. A. (2018). The immune landscape of cancer. *Immunity* 48, 812-830. e814.






902 Travis, W. D., Brambilla, E., Noguchi, M., Nicholson, A. G., Geisinger, K. R., Yatabe, Y., Beer, D. G., Powell,  
903 C. A., Riely, G. J., Van Schil, P. E., *et al.* (2011). International association for the study of lung  
904 cancer/american thoracic society/european respiratory society international multidisciplinary  
905 classification of lung adenocarcinoma. *Journal of thoracic oncology : official publication of the*  
906 *International Association for the Study of Lung Cancer* 6, 244-285.

907 Tschopp, J., Masson, D., and Stanley, K. K. (1986). Structural/functional similarity between proteins  
908 involved in complement- and cytotoxic T-lymphocyte-mediated cytolysis. *Nature* 322, 831-834.

909 Van Loo, P., Nordgard, S. H., Lingjaerde, O. C., Russnes, H. G., Rye, I. H., Sun, W., Weigman, V. J.,  
910 Marynen, P., Zetterberg, A., Naume, B., *et al.* (2010). Allele-specific copy number analysis of tumors.  
911 Proc Natl Acad Sci U S A *107*, 16910-16915.  
912 Vogelstein, B., Papadopoulos, N., Velculescu, V. E., Zhou, S., Diaz, L. A., Jr., and Kinzler, K. W. (2013).  
913 Cancer genome landscapes. *Science* *339*, 1546-1558.  
914 Wang, J., Jiang, D., Zheng, X., Li, W., Zhao, T., Wang, D., Yu, H., Sun, D., Li, Z., Zhang, J., *et al.* (2020).  
915 Tertiary Lymphoid Structure and CD8 T Cell Exclusion in Minimally Invasive Adenocarcinoma. medRxiv,  
916 2020.2008.2003.20166991.  
917 Wang, X., Zhang, B., Yang, Y., Zhu, J., Cheng, S., Mao, Y., Feng, L., and Xiao, T. (2019). Characterization of  
918 Distinct T Cell Receptor Repertoires in Tumor and Distant Non-tumor Tissues from Lung Cancer Patients.  
919 Genomics Proteomics Bioinformatics *17*, 287-296.  
920 Weichert, W., and Warth, A. (2014). Early lung cancer with lepidic pattern: adenocarcinoma in situ,  
921 minimally invasive adenocarcinoma, and lepidic predominant adenocarcinoma. *Current opinion in*  
922 *pulmonary medicine* *20*, 309-316.  
923 Wherry, E. J., and Kurachi, M. (2015). Molecular and cellular insights into T cell exhaustion. *Nat Rev*  
924 *Immunol* *15*, 486-499.  
925 Yarchoan, M., Johnson III, B. A., Lutz, E. R., Laheru, D. A., and Jaffee, E. M. (2017). Targeting neoantigens  
926 to augment antitumour immunity. *Nature Reviews Cancer* *17*, 209.




927



**A****B****C****D****E**






**A****C****B**

**Figure S1**


**A**

CD47: p-value = 5.947e-04




**B**

CD276: p-value = 8.774e-10




**C**

CTLA4: p-value = 1.400e-04




**D**

ENTPD1: p-value = 1.336e-05




**E**

GZMB: p-value = 5.438e-10



**F**


PRF1: p-value = 1.913e-08



**Figure S2**


**A**

**CD19: p-value = 2.846e-07**




**B**

**MS4A1: p-value = 2.021e-05**




**C**

**CXCL13: p-value = 6.515e-06**




**D**

**CXCR5: p-value = 2.281e-05**



**E**

**CCL19: p-value = 4.476e-07**



**F**

**CCR7: p-value = 4.230e-07**






Figure S3




**Figure S4**


**A**




**B**



**C**



**D**



**Figure S5**






Figure S6

Panel 1




Panel 2






**Figure S7**


**A**



**B**




**C**




**Figure S8**

**A**





Normal

**B**



ADC


Figure S9



# Figure S10


## A

— % Top 10 T-cell clones —




## B

— % Top 100 T-cell clones —




## C

— % Top 200 T-cell clones —









## D

— % Top 500 T-cell clones —




**Figure S11**




**Figure S12**


**A**




**B**




**C**




**D**









**E**







**F**



**Figure S13****A****B****C****D****E****F**


**Figure S14**






**Figure S15**


**A**




**B**




**C**




**D**



**E**




**F**



**Figure S16**

**A**



**B**






Figure S17




**Figure S18**


**A**



**B**



**C**



**D**

